I don't believe his argument was that pharma's were kicking down the door to partner. As I understand it, the point was that there is interest, which I believe the evidence supports.
I didn't state that was his argument. It's my argument for why the science only may be great, or at least 'early'.
BD is the one company that we know has seen LymPro 'up close'.
Whether an offer was made in either direction between BD and AMBS is unknowable. As for interest from other pharma companies? No hard evidence for that either.